Drugs / DD01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04812262 | Feb 2021 → Dec 2022 | NAFLD1, type 2 diabetes mellitus | Neuraly, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06410924 | Jun 2024 → May 2025 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Neuraly, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DD01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04812262 ↗ |
| Action | Activate | “Dual GLP-1 and glucagon receptor agonist” NCT06410924 ↗ |
| Modality | Peptide | “The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.” NCT04812262 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT04812262 ↗ |